10x Genomics (TXG) Total Current Liabilities (2018 - 2026)

10x Genomics (TXG) has 9 years of Total Current Liabilities data on file, last reported at $113.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 5.28% year-over-year to $113.6 million; the trailing twelve-month figure through Mar 2026 stood at $113.6 million (up 5.28% YoY), and the FY2025 full-year result was $153.5 million, up 30.45% from the prior year.
• Total Current Liabilities slipped to $113.6 million in Q1 2026, from $153.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $153.5 million in Q4 2025 to a low of $94.4 million in Q1 2022.
• A 5-year average of $118.0 million and a median of $113.6 million in 2026 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities retreated 21.65% in 2022 and surged 30.45% in 2025, its largest moves.
• Tracing TXG's Total Current Liabilities over 5 years: stood at $131.0 million in 2022, then slipped by 2.9% to $127.2 million in 2023, then retreated by 7.49% to $117.6 million in 2024, then soared by 30.45% to $153.5 million in 2025, then dropped by 25.97% to $113.6 million in 2026.
• Business Quant data shows TXG's Total Current Liabilities at $113.6 million in Q1 2026, $153.5 million in Q4 2025, and $147.3 million in Q3 2025.